Alumis

Graphic image of a red thumbs down against a blue background
Biotech

Investor pressures Acelyrin to exit Alumis merger and liquidate

Trium Capital set out its case for voting against a deal it argues is worse for shareholders than liquidating the biotech.
Nick Paul Taylor Apr 30, 2025 10:30am
puzzle pact

Kaken pens $180M pact for Alumis' lead TYK2 inhibitor in Japan

Mar 25, 2025 6:55am
blocks with checks and crosses

Acelyrin turns down surprise Concentra buyout offer

Mar 4, 2025 10:26am